Pre-vaccination prevalence and distribution of high-risk human papillomavirus (HPV) types in Slovenian women: A cervical cancer screening based study

Vaccine

Volumn 30, Issue 2, 2012, Pages 116-120

  Učakar, Veronika ^a   Poljak, Mario ^b   Klavs, Irena ^a  

^a NATIONAL INSTITUTE OF PUBLIC HEALTH   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Cervical cancer; HPV; Prevalence; Screening; Slovenia

Indexed keywords

ADULT; ARTICLE; CANCER SCREENING; DISEASE SEVERITY; DNA SCREENING; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 66; HUMAN PAPILLOMAVIRUS TYPE 68; MAJOR CLINICAL STUDY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; SLOVENIA; UTERINE CERVIX CANCER; UTERINE CERVIX DISEASE; VACCINATION; WART VIRUS;

ADULT; CERVIX UTERI; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; SLOVENIA; VIROLOGY;

EID: 84355162012     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.10.066     Document Type: Article

References (20)

1. Trottier H., Franco E.L. The epidemiology of genital human papillomavirus infection. Vaccine 2006, 24(SUPPL. 1):S1-S15.
2. Castle P.E., Schiffman M., Wheeler C.M., Wentzensen N., Gravitt P.E. Impact of improved classification on the association of human papillomavirus with cervical precancer. Am J Epidemiol 2010, 171:155-163.
3. Bouvard V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., et al. A review of human carcinogens - Part B: biological agents. Lancet Oncol 2009, 10:321-322.
4. Bosch F.X., Lorincz A., Munoz N., Meijer C.J.L.M., Shah K.V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002, 55:244-265.
5. Muñoz N., Castellsagué X., de González A.B., Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006, 24(SUPPL. 3):1-10.
6. de Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11:1048-1056.
7. de Sanjosé S., Diaz M., Castellsagué X., Clifford G., Bruni L., Muñoz N., et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007, 7:453-459.
8. Clifford G.M., Gallus S., Herrero R., Muñoz N., Snijders P.J., Vaccarella S., et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005, 366:991-998.
9. De Vuyst H., Clifford G., Li N., Franceschi S. HPV infection in Europe. Eur J Cancer 2009, 45:2632-2639.
10. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356:1915-1927. FUTURE II Study Group.
11. European Medicines Agency. Silgard. Summary of product characteristics. Available at: [accessed on: 10.3.2011]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000732/WC500051549.pdf.
12. Paavonen J., Naud P., Salmerón J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
13. European Medicines Agency. Cervarix. Summary of product characteristics. Available at: [accessed on: 10.3.2011]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000721/WC500024632.pdf.
14. Nicula F.A., Anttila A., Neamtiu L., Zakelj M.P., Tachezy R., Chil A., et al. Challenges in starting organised screening programmes for cervical cancer in the new member states of the European Union. Eur J Cancer 2009, 45:2679-2684.
15. Society for gynecological oncology, colposcopy and cervical pathology. Slovenian guidelines for management of pathological cervical smears. In Slovene: ZdruŽenje za ginekoloŠko onkologijo, kolposkopijo in cervikalno patologijo. Smernice za celostno obravnavo Žensk s predrakavimi spremembami materničnega vratu. Available at: [accessed on: 6.2.2011]. http://zora.onko-i.si/data/C1%20-%20Smernice%20za%20celostno%20obravnavo.pdf.
16. Poljak M., OŠtrbenk A., Seme K., Učakar V., Hillemanns P., Vrtačnik Bokal E., et al. Comparison of clinical and analytical performance of the Abbott RealTime High Risk HPV Test and Hybrid Capture 2 in population-based cervical cancer screening. J Clin Microbiol 2011, 49:1721-1729.
17. Poljak M., Kocjan B.J. Commercially available assays for multiplex detection of alpha human papillomaviruses. Exp Rev Anti Infect Ther 2010, 8:1139-1162.
18. Huang S., Tang N., Mak W.B., Erickson B., Salituro J., Li Y., et al. Principles and analytical performance of Abbott RealTime High Risk HPV Test. J Clin Virol 2009, 45:S13-S17.
19. Eklund C., Zhou T., Dillner J. WHO Human Papillomavirus Laboratory Network. Global proficiency study of human papillomavirus genotyping. J Clin Microbiol 2010, 48:4147-4155.
20. Slovenian National Cervical Cancer Screening Programme (DP ZORA) in pictures; January 2011. In Slovene: DP ZORA v slikah. Available at: [accessed on 26.4.2011]. http://zora.onko-i.si/data/DP_ZORA_v_slikah_2011.pdf.